Annual CFF
$63.77 M
+$48.31 M+312.34%
December 31, 2021
Summary
- As of February 10, 2025, PHAS annual cash flow from financing activities is $63.77 million, with the most recent change of +$48.31 million (+312.34%) on December 31, 2021.
- During the last 3 years, PHAS annual CFF has fallen by -$1.02 million (-1.58%).
Performance
PHAS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
-$415.00 K
-$236.00 K-131.84%
June 30, 2022
Summary
- As of February 10, 2025, PHAS quarterly cash flow from financing activities is -$415.00 thousand, with the most recent change of -$236.00 thousand (-131.84%) on June 30, 2022.
- Over the past year, PHAS quarterly CFF has increased by +$750.00 thousand (+64.38%).
Performance
PHAS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
$5.17 M
+$750.00 K+16.97%
June 30, 2022
Summary
- As of February 10, 2025, PHAS TTM cash flow from financing activities is $5.17 million, with the most recent change of +$750.00 thousand (+16.97%) on June 30, 2022.
- Over the past year, PHAS TTM CFF has dropped by -$55.34 million (-91.46%).
Performance
PHAS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PHAS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +312.3% | +64.4% | -91.5% |
| 3 y3 years | -1.6% | -100.8% | -90.3% |
| 5 y5 years | +251.1% | - | -90.3% |
PHAS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | at low | -105.9% | at low | -91.9% | -14.5% |
| 5 y | 5-year | at high | -75.7% | -100.7% | +220.2% | -92.0% | -14.5% |
| alltime | all time | -1.6% | -100.0% | -100.7% | +220.2% | -95.4% | -100.0% |
PhaseBio Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$415.00 K(+131.8%) | $5.17 M(+17.0%) |
| Mar 2022 | - | -$179.00 K(-102.5%) | $4.42 M(-93.1%) |
| Dec 2021 | $63.77 M(+312.3%) | $7.09 M(-633.7%) | $63.77 M(+12.2%) |
| Sep 2021 | - | -$1.33 M(+14.1%) | $56.85 M(-6.1%) |
| Jun 2021 | - | -$1.17 M(-102.0%) | $60.51 M(-6.5%) |
| Mar 2021 | - | $59.17 M(>+9900.0%) | $64.74 M(+318.6%) |
| Dec 2020 | $15.47 M(-71.1%) | $169.00 K(-92.8%) | $15.47 M(-23.3%) |
| Sep 2020 | - | $2.33 M(-23.8%) | $20.18 M(+12.7%) |
| Jun 2020 | - | $3.06 M(-69.1%) | $17.91 M(-71.9%) |
| Mar 2020 | - | $9.90 M(+102.9%) | $63.75 M(+19.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $53.53 M(-17.4%) | $4.88 M(+7523.4%) | $53.53 M(-42.0%) |
| Sep 2019 | - | $64.00 K(-99.9%) | $92.27 M(-17.2%) |
| Jun 2019 | - | $48.91 M(<-9900.0%) | $111.39 M(+72.8%) |
| Mar 2019 | - | -$322.00 K(-100.7%) | $64.47 M(-0.5%) |
| Dec 2018 | $64.80 M(+256.7%) | $43.62 M(+127.3%) | $64.80 M(+205.9%) |
| Sep 2018 | - | $19.19 M(+861.7%) | $21.18 M(+961.7%) |
| Jun 2018 | - | $2.00 M(>+9900.0%) | $2.00 M(>+9900.0%) |
| Mar 2018 | - | $0.00 | $0.00 |
| Dec 2017 | $18.17 M(>+9900.0%) | - | - |
| Dec 2016 | $1000.00 | - | - |
FAQ
- What is PhaseBio Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for PhaseBio Pharmaceuticals?
- What is PhaseBio Pharmaceuticals annual CFF year-on-year change?
- What is PhaseBio Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for PhaseBio Pharmaceuticals?
- What is PhaseBio Pharmaceuticals quarterly CFF year-on-year change?
- What is PhaseBio Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for PhaseBio Pharmaceuticals?
- What is PhaseBio Pharmaceuticals TTM CFF year-on-year change?
What is PhaseBio Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of PHAS is $63.77 M
What is the all time high annual CFF for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals all-time high annual cash flow from financing activities is $64.80 M
What is PhaseBio Pharmaceuticals annual CFF year-on-year change?
Over the past year, PHAS annual cash flow from financing activities has changed by +$48.31 M (+312.34%)
What is PhaseBio Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of PHAS is -$415.00 K
What is the all time high quarterly CFF for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals all-time high quarterly cash flow from financing activities is $59.17 M
What is PhaseBio Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, PHAS quarterly cash flow from financing activities has changed by +$750.00 K (+64.38%)
What is PhaseBio Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of PHAS is $5.17 M
What is the all time high TTM CFF for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals all-time high TTM cash flow from financing activities is $111.39 M
What is PhaseBio Pharmaceuticals TTM CFF year-on-year change?
Over the past year, PHAS TTM cash flow from financing activities has changed by -$55.34 M (-91.46%)